Adagene Reports Updated Phase 1b/2 Study Data
Ticker: ADAG · Form: 6-K · Filed: May 22, 2025 · CIK: 1818838
| Field | Detail |
|---|---|
| Company | Adagene INC. (ADAG) |
| Form Type | 6-K |
| Filed Date | May 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, biotech, press-release
TL;DR
Adagene dropped updated Phase 1b/2 data for Muzast, check the press release for deets.
AI Summary
Adagene Inc. filed a Form 6-K on May 22, 2025, to report updated data from its Phase 1b/2 study of Muzast. The press release, Exhibit 99.1, details these findings, though specific data points and their implications are not detailed in this filing document.
Why It Matters
This filing provides an update on clinical trial progress for Adagene's drug candidate, Muzast, which could impact future development and investor sentiment.
Risk Assessment
Risk Level: medium — Clinical trial data updates can significantly impact a biotech company's stock price, introducing volatility.
Key Players & Entities
- Adagene Inc. (company) — Registrant
- Peter Luo (person) — Chief Executive Officer
- Muzast (drug) — Drug candidate in Phase 1b/2 study
FAQ
What is the specific nature of the updated data from the Phase 1b/2 study of Muzast?
The filing indicates updated data was announced in a press release (Exhibit 99.1), but the specific details of this data are not included within the 6-K document itself.
When was this Form 6-K filed?
The Form 6-K was filed on May 22, 2025.
Who signed this report on behalf of Adagene Inc.?
Peter Luo, Chief Executive Officer, signed the report on behalf of Adagene Inc.
What is Adagene Inc.'s principal executive office address?
Adagene Inc.'s principal executive offices are located at 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China.
What is the SEC file number for Adagene Inc.?
Adagene Inc.'s SEC file number is 001-39997.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 22, 2025 by Peter Luo regarding Adagene Inc. (ADAG).